Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Иннейт ФармаfiledCriticalИннейт Фарма
Priority claimed from PCT/EP2018/077217external-prioritypatent/WO2019068907A1/en
Publication of EA202090549A1publicationCriticalpatent/EA202090549A1/en
В настоящем изобретении предложены способы применения соединений, которые ингибируют ферментативную активность растворимого CD39 человека, для лечения рака, включая, но не ограничиваясь, лечение типов рака, характеризуемых экспрессирующими CD73 клетками.The present invention provides methods of using compounds that inhibit the enzymatic activity of human soluble CD39 for the treatment of cancer, including, but not limited to, treatment of cancers characterized by CD73 expressing cells.
EA202090549A2018-06-182018-10-05
RESTORATION OF T-CELLS ACTIVITY THROUGH THE CD39 / CD73 SYSTEM
EA202090549A1
(en)